{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T09:03:59Z","timestamp":1790240639743,"version":"4.1.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,5,1]],"date-time":"2024-05-01T00:00:00Z","timestamp":1714521600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T00:00:00Z","timestamp":1715212800000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Heliyon"],"published-print":{"date-parts":[[2024,5]]},"DOI":"10.1016\/j.heliyon.2024.e31011","type":"journal-article","created":{"date-parts":[[2024,5,9]],"date-time":"2024-05-09T23:55:36Z","timestamp":1715298936000},"page":"e31011","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) omicron sub-variants in Bangladesh cause mild COVID-19 and associate with similar antibody responses irrespective of natural infection or vaccination history"],"prefix":"10.1016","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5617-4139","authenticated-orcid":false,"given":"Simon D.","family":"Lytton","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Asish Kumar","family":"Ghosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rakibul Hassan","family":"Bulbul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tasnim","family":"Nafisa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashid","family":"Mamunur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Meier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olfert","family":"Landt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Kaiser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.heliyon.2024.e31011_bib1","unstructured":"John Hopkins Coronavirus Resource Center https:\/\/coronavirus.jhu.edu\/data (accessed March 10, 2023)."},{"key":"10.1016\/j.heliyon.2024.e31011_bib3","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.3390\/ijms24032264","article-title":"Convergent evolution in SARS-CoV-2 spike creates a variant soup from which new COVID-19 waves emerge","volume":"24","author":"Focosi","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.heliyon.2024.e31011_bib4","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.heliyon.2024.e31011_bib5","first-page":"162","article-title":"SARS-CoV-2 variant biology: immune escape, transmission and fitness","volume":"21","author":"Carabelli","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.heliyon.2024.e31011_bib6","unstructured":"Bangladesh Directorate General of Health Services, Ministry of Health and Family Welfare. Coronavirus COVID-19 Dashboard. (accessed on March 30, 2023). http:\/\/103.247.238.92\/webportal\/pages\/covid19.php."},{"key":"10.1016\/j.heliyon.2024.e31011_bib7","article-title":"Delta variant (B.1.617.2) of SARS-CoV-2: mutations, impact, challenges and possible solutions","volume":"18","author":"Dhawan","year":"2022","journal-title":"Hum Vac Immunther"},{"key":"10.1016\/j.heliyon.2024.e31011_bib8","doi-asserted-by":"crossref","first-page":"100159","DOI":"10.1016\/j.infpip.2021.100159","article-title":"Bangladesh reported delta variant of coronavirus among its citizen: actionable items to tackle the potential massive third wave","volume":"3","author":"Daria","year":"2021","journal-title":"Infect. Prev. Pract."},{"key":"10.1016\/j.heliyon.2024.e31011_bib9","first-page":"1","article-title":"The emergence of SARS-CoV-2 variants in Dhaka city, Bangladesh","volume":"1","author":"Rahman","year":"2021","journal-title":"Transbound. Emerg. Dis"},{"key":"10.1016\/j.heliyon.2024.e31011_bib10","article-title":"COVID-19 rise in Bangladesh correlates with increasing detection of B.1.351 variant","volume":"6","author":"Saha","year":"2021","journal-title":"Brit. Med. J. Glob. Health"},{"key":"10.1016\/j.heliyon.2024.e31011_bib11","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1080\/21645515.2021.1963601","article-title":"Impact of SARS-CoV-2 delta variant (B.1.617.2) in surging second wave of COVID-19 and efficacy of vaccines in tackling the ongoing pandemic","volume":"17","author":"Tareq","year":"2021","journal-title":"Hum. Vaccines Immunother."},{"key":"10.1016\/j.heliyon.2024.e31011_bib12","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1016\/S1473-3099(22)00028-7","article-title":"COVID-19 vaccine inequity, dependency, and production capability in low-income and middle-income countries: the case of Bangladesh","volume":"22","author":"Mahmud-Al-Rafat","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e31011_bib13","doi-asserted-by":"crossref","first-page":"e1471","DOI":"10.1016\/S2214-109X(21)00227-8","article-title":"Coming to terms with COVID-19 personally and professionally in Bangladesh","volume":"9","author":"Saha","year":"2021","journal-title":"Lancet Global Health"},{"key":"10.1016\/j.heliyon.2024.e31011_bib14","doi-asserted-by":"crossref","first-page":"637","DOI":"10.3390\/pathogens10060637","article-title":"SARS-CoV-2 Nucleocapsid detection in Bangladeshi Covid-19 is not affected by Dengue infection","volume":"10","author":"Lytton","year":"2021","journal-title":"MDPI Pathogens"},{"key":"10.1016\/j.heliyon.2024.e31011_bib15","doi-asserted-by":"crossref","DOI":"10.1002\/hsr2.1134","article-title":"SARS CoV-2 omicron variants in Bangladesh: pandemic to endemic","volume":"6","author":"Jubair","year":"2023","journal-title":"Health Sci Rep"},{"key":"10.1016\/j.heliyon.2024.e31011_bib16","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.3390\/vaccines10111959","article-title":"Clinical presentation of COVID-19 and antibody responses in Bangladeshi patients infected with the Delta or Omicron variant of SARS-CoV-2","volume":"10","author":"Ghosh","year":"2022","journal-title":"MDPI Vaccines"},{"key":"10.1016\/j.heliyon.2024.e31011_bib17","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.3390\/v13112310","article-title":"Molecular and serological characterization of the SARS\u2010CoV\u20102 delta variant in Bangladesh in 2021","volume":"13","author":"Ghosh","year":"2021","journal-title":"MDPI Viruses"},{"key":"10.1016\/j.heliyon.2024.e31011_bib18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1186\/s41182-021-00360-w","article-title":"Emergence of highly infectious SARS-CoV-2 variants in Bangladesh: the need for systematic genetic surveillance as a public health strategy","volume":"49","author":"Hasan","year":"2021","journal-title":"Trop. Med. Health BMC"},{"key":"10.1016\/j.heliyon.2024.e31011_bib19","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.cell.2020.06.043","article-title":"COVID-19 Genomics Group, Tracking changes in SARS-CoV-2 spike: evidence that D614G increases infectivity of the COVID-19 virus","volume":"182","author":"Korber","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e31011_bib20","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/s41579-023-00878-2","article-title":"The evolution of SARS-CoV-2","volume":"21","author":"Markov","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.heliyon.2024.e31011_bib21","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/S1473-3099(23)00051-8","article-title":"Enhanced transmissibility, infectivity, and immune resistance of the SARSCoV-2 omicron XBB.1.5 variant","volume":"23","author":"Uriu","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.heliyon.2024.e31011_bib22","article-title":"Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa","author":"Pulliam","year":"2021","journal-title":"medRxiv"},{"key":"10.1016\/j.heliyon.2024.e31011_bib23","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1097\/JS9.0000000000000246","article-title":"The SARS-CoV-2 Omicron recombinant subvariants XBB, XBB.1, and XBB.1.5 are expanding rapidly with unique mutations, antibody evasion, and immune escape properties \u2013 an alarming global threat of a surge in COVID-19 cases again?","volume":"109","author":"Chakraborty","year":"2023","journal-title":"Int. J. Surg."},{"key":"10.1016\/j.heliyon.2024.e31011_bib24","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41467-023-38435-3","article-title":"Virological characteristics of the SARS-CoV-2 XBB variant derived from recombination of two Omicron subvariants","volume":"14","author":"Tamura","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.heliyon.2024.e31011_bib25","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.cell.2022.12.018","article-title":"Alarming antibody evasion properties of rising SARS-CoV-2 BQ and XBB subvariants","volume":"186","author":"Wang","year":"2023","journal-title":"Cell"},{"key":"10.1016\/j.heliyon.2024.e31011_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2023.112271","article-title":"Rapid escape of new SARS-CoV-2 Omicron variants from BA.2-directed antibody responses","volume":"42","author":"Dijokaite-Guraliuc","year":"2023","journal-title":"Cell Rep."},{"key":"10.1016\/j.heliyon.2024.e31011_bib28","first-page":"1","article-title":"Coding-complete genome sequences of 40 SARS-CoV-2 omicron XBB, XBB.1, and XBB.2 sublineage strains in Bangladesh","volume":"12","author":"Habib","year":"2023","journal-title":"ASM J Microbiol Res Ann."},{"key":"10.1016\/j.heliyon.2024.e31011_bib29","doi-asserted-by":"crossref","first-page":"1728","DOI":"10.3390\/vaccines10101728","article-title":"Polz-Dacewicz M. Antibody responses after the SARS CoV-2 infection with the delta and omicron variant","volume":"10","author":"Blaszczuk","year":"2022","journal-title":"MDPI Vaccines"},{"key":"10.1016\/j.heliyon.2024.e31011_bib30","doi-asserted-by":"crossref","first-page":"1045","DOI":"10.1007\/s15010-021-01651-4","article-title":"IgG antibody response against nucleocapsid and spike protein post-SARS-CoV-2 infection","volume":"49","author":"Choudhary","year":"2021","journal-title":"Infection"},{"key":"10.1016\/j.heliyon.2024.e31011_bib31","first-page":"198","article-title":"Seroprevalence of SARS-CoV-2 antibodies in Bangladesh related to novel coronavirus infection","author":"Bhuiyan","year":"2022","journal-title":"Int J Infect Dis Regions"},{"key":"10.1016\/j.heliyon.2024.e31011_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0010102","article-title":"Disease characteristics and serological responses in patients with differing severity of Covid-19 infection: a longitudinal cohort study in Dhaka, Bangladesh","volume":"16","author":"Akter","year":"2022","journal-title":"PLoS Negl Trop Dis"}],"container-title":["Heliyon"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024070427?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2405844024070427?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T08:24:39Z","timestamp":1790238279000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2405844024070427"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2024,5]]}},"alternative-id":["S2405844024070427"],"URL":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31011","relation":{},"ISSN":["2405-8440"],"issn-type":[{"value":"2405-8440","type":"print"}],"subject":[],"published":{"date-parts":[[2024,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The severe acute respiratory syndrome coronavirus-2 (SARS CoV-2) omicron sub-variants in Bangladesh cause mild COVID-19 and associate with similar antibody responses irrespective of natural infection or vaccination history","name":"articletitle","label":"Article Title"},{"value":"Heliyon","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.heliyon.2024.e31011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"e31011"}}